OptimizeRx Corp — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
OptimizeRx terminated Edward Stelmakh as Chief Financial & Strategy Officer effective December 31, 2026, paying $450,000 severance over 24 months plus $247,500 bonus, plus 12 months COBRA reimbursement, and continued equity vesting (55,644 shares) as Strategic Advisor through 2027. Andrew D'Silva promoted to CFO at $375,000 base salary + 50% bonus target; Heather Favazza promoted to Chief Accounting Officer at $325,000 base salary + 40% bonus target, both effective January 1, 2027. Stelmakh remains as advisor during transition period (Jan–Dec 2027).
Why this rating
Executive transition is planned succession with no immediate business disruption; $697.5K severance + benefits (~0.3% of market cap) is material but manageable. Stelmakh's departure removes a 5-year CFO but D'Silva/Favazza internally promoted, suggesting stability. Revenue down 30% YoY; adjusted EBITDA down 15% YoY—core issue is business performance, not leadership change.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.